---
title: "Relapsed refractory of treatment and prognosis of multiple myeloma (MM)"
slug: "relapsed-refractory-of-treatment-and-prognosis-of-multiple-myeloma-mm"
date: "2023-05-26"
enableToc: false
tags:
- building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[treatment and prognosis of multiple myeloma (MM)]]

# Relapsed refractory of treatment and prognosis of multiple myeloma (MM)

* HSCT (if good prior response, no prior HSCT),
* Elo-PD,
* Dara-PD,
* venetoclax (anti-Bcl-2) + dex in t(11;14);
* rarely use Allo-SCT. CAR-T w/ idecabtagene vicleucel (anti-B-cell maturation antigen) after >3 prior Rx: response rates >70% (NEJM 2019;380:1726 & 2021;384:705).
